The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

doi 10.1101/772061
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

GATA3 as a Master Regulator and Therapeutic Target in Ovarian High-Grade Serous Carcinoma Stem Cells

International Journal of Cancer
Cancer ResearchOncology
2018English

Retinoblastoma Pathway Deregulatory Mechanisms Determine Clinical Outcome in High-Grade Serous Ovarian Carcinoma

Modern Pathology
Forensic MedicinePathology
2013English

HMGA2: A Biomarker Significantly Overexpressed in High-Grade Ovarian Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2010English

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Amplification of the Ch19p13.2 NACC1 Locus in Ovarian High-Grade Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2011English

Erratum To: Tubal Precursor Lesions in High Grade Serous Ovarian Carcinoma

Indian Journal of Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Characteristics of 10-Year Survivors of High-Grade Serous Ovarian Carcinoma

Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Targeting IDH1 as a Pro-Senescent Therapy in High-Grade Serous Ovarian Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy